In the present manuscript, we also demonstrate that co-targeting of NOA, without keeping the TKI, is able to affect the main properties of TKI resistance, inducing reduction of cell viability and migration ability, cell-cycle arrest, and EMT inhibition in both EGFR- and KRAS-mutant NSCLC models. Here, KRAS is linked to non-small cell lung carcinoma.